During the MPN Hub Steering Committee Meeting in May 2026, Andreas Reiter, University Hospital Mannheim, Mannheim, DE, delivered a presentation on targeting KIT in advanced systemic mastocytosis (AdvSM). In this presentation, Reiter discusses the rationale for KIT inhibition, and key efficacy and safety data for KIT-targeting therapies in AdvSM. The presentation highlights data from key trials, including the depth of molecular response with KIT-targeting therapies and its correlation with clinical benefit, and concludes with an overview of future directions in KIT inhibition for patients with AdvSM.
This educational resource is independently supported by Blueprint Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}